Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Yamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V. by August 2005)
Woman and Man Max 99 years
Yamanouchi Europe B.V. (to be renamed Astellas Pharma Europe B.V. by August 2005)
Update Il y a 4 ans
A Phase II, Multicenter, Open-Label Study of YM155 in Patients With Advanced Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) Who Have Failed One or Two Prior Lines of Therapy, at Least One of Which Contained a Platinum Agent
To evaluate the efficacy of YM155 based on objective tumor response rate (CR+PR) in patients with measurable disease based on RECIST criteria
Country
None
organs
None
Specialty
None
unknown
More information